Zenas BioPharma (NASDAQ:ZBIO) Stock Keeps “Outperform” Rating at Wedbush

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “outperform” rating restated by Wedbush in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $45.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 68.27% from the company’s current price.

A number of other brokerages have also issued reports on ZBIO. HC Wainwright reiterated a “buy” rating and issued a $44.00 price target on shares of Zenas BioPharma in a report on Wednesday. Wall Street Zen raised Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Guggenheim reiterated a “buy” rating and set a $55.00 target price on shares of Zenas BioPharma in a report on Wednesday. Finally, Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and an average target price of $45.71.

Zenas BioPharma Trading Down 0.1%

Zenas BioPharma stock traded down $0.02 during mid-day trading on Wednesday, hitting $26.74. The company’s stock had a trading volume of 11,442 shares, compared to its average volume of 815,364. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. The company has a 50 day moving average of $31.47 and a 200-day moving average of $25.08. Zenas BioPharma has a one year low of $13.50 and a one year high of $44.60. The stock has a market cap of $1.74 billion, a PE ratio of -2.97 and a beta of -1.04.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The firm had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $15.00 million. On average, research analysts anticipate that Zenas BioPharma will post -5.81 EPS for the current year.

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors have recently modified their holdings of the business. Quantbot Technologies LP acquired a new stake in Zenas BioPharma in the second quarter valued at approximately $49,000. Jupiter Topco LLC purchased a new position in Zenas BioPharma during the second quarter valued at $201,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Zenas BioPharma in the second quarter valued at about $204,000. ProShare Advisors LLC purchased a new stake in shares of Zenas BioPharma during the fourth quarter worth about $211,000. Finally, Sei Investments Co. purchased a new position in Zenas BioPharma in the 1st quarter valued at about $242,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.